Keyphrases
Sentinel Lymph Node
100%
Randomized Phase III Trial
100%
Node-negative
100%
Metastatic Melanoma
100%
Melanoma Follow-up
100%
Melanoma Patients
75%
Hazard Ratio
50%
Confidence Interval
50%
National Guidelines
50%
Survival Outcomes
50%
Self-examination
50%
Netherlands
25%
Adult Patients
25%
United Kingdom
25%
In Cancer
25%
Quality of Life
25%
Randomized Controlled Trial
25%
Patient-Reported Outcomes Measurement Information System (PROMIS)
25%
Patient Satisfaction Score
25%
Low Intensity
25%
Group Control
25%
Detection Method
25%
Primary Melanoma
25%
Evidence-based Guidelines
25%
Disease-free Survival
25%
Detection Rate
25%
Diagnostic Delay
25%
Cancer Center
25%
Cancer Stage
25%
Group Effect
25%
Follow-up Protocol
25%
Reduced Intensity
25%
American Joint Committee on Cancer
25%
Recurrence Detection
25%
Patient Acceptance
25%
SAFE Strategy
25%
Reduced Frequency
25%
Medicine and Dentistry
Nodular Melanoma
100%
Cutaneous Melanoma
100%
Randomized Clinical Trial
100%
Sentinel Node
100%
Arm
40%
Hazard Ratio
40%
Self Examination
40%
Malignant Neoplasm
20%
Quality of Life
20%
Randomized Controlled Trial
20%
Patient-Reported Outcome
20%
Outcome Assessment
20%
Recurrent Disease
20%
Cancer Staging
20%
Patient Satisfaction
20%
Disease Free Survival
20%
Diagnostic Delay
20%
Arm Disease
20%
Nursing and Health Professions
Melanoma
100%
Cutaneous Melanoma
100%
Practice Guideline
60%
Hazard Ratio
40%
Confidence Interval
40%
Self Examination
40%
Quality of Life
20%
Diagnosis
20%
Outcome Assessment
20%
Compliance
20%
Cancer Center
20%
Recurrent Disease
20%
Patient Satisfaction
20%
Patient-Reported Outcome
20%
Cancer Staging
20%
Disease Free Survival
20%
Arm Disease
20%